SAN DIEGO --(BUSINESS WIRE)--Mar. 22, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and 12 months ended December 31, 2020 after the market closes on Monday, March 29, 2021
Company presentation features neuro-oncology program with goal of becoming standard of care for diagnosis, characterization and monitoring of metastatic spread of solid tumors to the central nervous system (CNS) Provides update on COVID-19 testing with more than 300,000 samples received SAN DIEGO
SAN DIEGO --(BUSINESS WIRE)--Mar. 3, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 38,250 shares of its common stock to six new employees.
COVID-19 test, based on Aegea’s next-generation COVID-19 assay kit using Switch-Blocker™ technology, may provide answers that support screening and managing patients SAN DIEGO --(BUSINESS WIRE)--Mar. 2, 2021-- Aegea Biotechnologies, Inc. , an innovative life science company with an extensive
Target Selector™ EGFR assays offer ultra-high sensitivity and require less tumor sample than most commercial assays SAN DIEGO --(BUSINESS WIRE)--Feb. 23, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will collaborate with Protean
Data to be presented at Molecular Med Tri-Con Virtual Conference SAN DIEGO --(BUSINESS WIRE)--Feb. 16, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will present data showing that its Target Selector™ molecular assay kit detects
SAN DIEGO --(BUSINESS WIRE)--Feb. 3, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, provides an update on its COVID-19 testing with more than 250,000 samples received to date for processing
SAN DIEGO --(BUSINESS WIRE)--Feb. 2, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, today announced that it has granted
SAN DIEGO --(BUSINESS WIRE)--Jan. 12, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular testing to provide physicians with clinically actionable information to improve patient outcomes, announces that President and CEO Michael W.
CEO Michael Nall to participate in diagnostics and devices panel discussion hosted by former FDA Commissioner Dr. Scott Gottlieb SAN DIEGO , Jan. 4, 2021 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to
